• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Staging of hepatocellular carcinoma.肝细胞癌的分期
J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S74-9. doi: 10.1016/j.jceh.2014.03.045. Epub 2014 Jun 6.
2
Validation and ranking of seven staging systems of hepatocellular carcinoma.肝细胞癌七种分期系统的验证与排名
Oncol Lett. 2017 Jul;14(1):705-714. doi: 10.3892/ol.2017.6222. Epub 2017 May 22.
3
Prognosis of unresectable hepatocellular carcinoma: comparison of seven staging systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese cohort.不可切除肝细胞癌的预后:中国队列中七种分期系统(TNM、奥田、巴塞罗那临床肝癌、CLIP、CUPI、日本综合分期系统、CIS)的比较
PLoS One. 2014 Mar 7;9(3):e88182. doi: 10.1371/journal.pone.0088182. eCollection 2014.
4
Treatment algorithms for managing hepatocellular carcinoma.肝细胞癌的治疗算法
J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S80-9. doi: 10.1016/j.jceh.2014.05.004. Epub 2014 Jun 6.
5
Comparison of staging systems of hepatocellular carcinoma.肝细胞癌分期系统的比较。
HPB Surg. 2011;2011:818217. doi: 10.1155/2011/818217. Epub 2011 Jun 27.
6
Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score).肝细胞癌预后分期系统(CLIP评分):其价值与局限性,以及一种新分期系统——日本综合分期评分(JIS评分)的提案。
J Gastroenterol. 2003;38(3):207-15. doi: 10.1007/s005350300038.
7
Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population.前瞻性验证中国大学预后指数并与其他分期系统在亚洲人群中的肝细胞癌进行比较。
J Gastroenterol Hepatol. 2011 Feb;26(2):340-7. doi: 10.1111/j.1440-1746.2010.06329.x.
8
Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems.目前的分期系统可对入组临床试验的晚期肝细胞癌患者的预后进行分类。
Br J Cancer. 2012 Nov 6;107(10):1672-7. doi: 10.1038/bjc.2012.466. Epub 2012 Oct 11.
9
Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery.CLIP、奥田、TNM和JIS分期系统对接受手术的肝细胞癌患者的预测价值评估。
J Gastroenterol Hepatol. 2005 May;20(5):765-71. doi: 10.1111/j.1440-1746.2005.03746.x.
10
Advanced hepatocellular carcinoma: which staging systems best predict prognosis?晚期肝细胞癌:哪种分期系统能更好地预测预后?
J Clin Oncol. 2010 Jun 10;28(17):2889-95. doi: 10.1200/JCO.2009.25.9895. Epub 2010 May 10.

引用本文的文献

1
Spatial heterogeneity reveals an evolutionary signature predicting therapeutic response and clinical outcomes in hepatocellular carcinoma.空间异质性揭示了预测肝细胞癌治疗反应和临床结果的进化特征。
Front Bioinform. 2025 Aug 18;5:1669236. doi: 10.3389/fbinf.2025.1669236. eCollection 2025.
2
Multi-feature weight factor extraction and survival risk assessment of hepatocellular carcinoma based on a clinical missing dataset-independent support vector machine.基于临床缺失数据集无关支持向量机的肝细胞癌多特征权重因子提取及生存风险评估
ILIVER. 2022 Aug 24;1(3):154-158. doi: 10.1016/j.iliver.2022.07.003. eCollection 2022 Sep.
3
Explainable machine learning model for predicting the transarterial chemoembolization response and subtypes of hepatocellular carcinoma patients.用于预测肝细胞癌患者经动脉化疗栓塞反应和亚型的可解释机器学习模型。
BMC Gastroenterol. 2025 Jul 7;25(1):503. doi: 10.1186/s12876-025-04105-5.
4
Sorafenib with or without co-interventions for hepatocellular carcinoma.索拉非尼联合或不联合其他干预措施治疗肝细胞癌。
Cochrane Database Syst Rev. 2025 Jun 26;6(6):CD015851. doi: 10.1002/14651858.CD015851.
5
The endoplasmic reticulum degradation-enhancing α-mannosidase-like protein 3 attenuates the unfolded protein response and has pro-survival and pro-viral roles in hepatoma cells and hepatocellular carcinoma patients.内质网降解增强α-甘露糖苷酶样蛋白3减弱未折叠蛋白反应,并在肝癌细胞和肝细胞癌患者中具有促生存和促病毒作用。
J Biomed Sci. 2025 Jan 22;32(1):11. doi: 10.1186/s12929-024-01103-9.
6
Construction of a random survival forest model based on a machine learning algorithm to predict early recurrence after hepatectomy for adult hepatocellular carcinoma.基于机器学习算法构建随机生存森林模型以预测成人肝细胞癌肝切除术后的早期复发。
BMC Cancer. 2024 Dec 25;24(1):1575. doi: 10.1186/s12885-024-13366-4.
7
Exploring the Impact of the β-Catenin Mutations in Hepatocellular Carcinoma: An In-Depth Review.探讨β-连环蛋白突变在肝细胞癌中的作用:深入综述。
Cancer Control. 2024 Jan-Dec;31:10732748241293680. doi: 10.1177/10732748241293680.
8
Machine Learning for Dynamic Prognostication of Patients With Hepatocellular Carcinoma Using Time-Series Data: Survival Path Versus Dynamic-DeepHit HCC Model.使用时间序列数据对肝细胞癌患者进行动态预后预测的机器学习:生存路径与动态深度命中肝癌模型
Cancer Inform. 2024 Oct 16;23:11769351241289719. doi: 10.1177/11769351241289719. eCollection 2024.
9
Mitotic catastrophe heterogeneity: implications for prognosis and immunotherapy in hepatocellular carcinoma.有丝分裂灾难异质性:对肝细胞癌预后和免疫治疗的影响
Front Immunol. 2024 Jul 1;15:1409448. doi: 10.3389/fimmu.2024.1409448. eCollection 2024.
10
Emerging Roles of Small Extracellular Vesicles in Gastrointestinal Cancer Research and Therapy.小细胞外囊泡在胃肠道癌研究与治疗中的新作用
Cancers (Basel). 2024 Jan 29;16(3):567. doi: 10.3390/cancers16030567.

本文引用的文献

1
[Value of (18)F-FDG PET/CT and CECT in detecting postoperative recurrence and extrahepatic metastasis of hepatocellular carcinoma in patients with elevated serum alpha-fetoprotein].[¹⁸F-FDG PET/CT与CT增强扫描在血清甲胎蛋白升高的肝细胞癌患者术后复发及肝外转移检测中的价值]
Nan Fang Yi Ke Da Xue Xue Bao. 2012 Nov;32(11):1615-9.
2
Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.BCLC 分期在预后分层方面的适用性与其他分期系统的比较:来自 1717 例未经治疗的肝细胞癌患者长期临床结局的单中心经验。
Liver Int. 2012 Aug;32(7):1120-7. doi: 10.1111/j.1478-3231.2012.02811.x. Epub 2012 Apr 23.
3
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南:肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
4
Comparison of staging systems of hepatocellular carcinoma.肝细胞癌分期系统的比较。
HPB Surg. 2011;2011:818217. doi: 10.1155/2011/818217. Epub 2011 Jun 27.
5
Comparison of 7 staging systems in north Indian cohort of hepatocellular carcinoma.印度北部肝细胞癌队列中7种分期系统的比较
Trop Gastroenterol. 2010 Oct-Dec;31(4):271-8.
6
Management of hepatocellular carcinoma: an update.肝细胞癌的管理:最新进展
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
7
Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population.前瞻性验证中国大学预后指数并与其他分期系统在亚洲人群中的肝细胞癌进行比较。
J Gastroenterol Hepatol. 2011 Feb;26(2):340-7. doi: 10.1111/j.1440-1746.2010.06329.x.
8
Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design.肝癌患者生存结局的地理差异:对未来临床试验设计的启示。
Contemp Clin Trials. 2010 Jan;31(1):55-61. doi: 10.1016/j.cct.2009.08.002. Epub 2009 Sep 6.
9
Clinical profile, etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India.印度一家三级医疗中心324例肝细胞癌患者的临床特征、病因及治疗结果
Oncology. 2009;77(3-4):162-71. doi: 10.1159/000231886. Epub 2009 Jul 28.
10
Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score.一种新的肝细胞癌预后分期系统的验证:生物标志物联合日本综合分期评分、传统日本综合分期评分与BALAD评分的比较
Oncology. 2008;75 Suppl 1:83-90. doi: 10.1159/000173428. Epub 2008 Dec 17.

肝细胞癌的分期

Staging of hepatocellular carcinoma.

作者信息

Duseja Ajay

机构信息

Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.

出版信息

J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S74-9. doi: 10.1016/j.jceh.2014.03.045. Epub 2014 Jun 6.

DOI:10.1016/j.jceh.2014.03.045
PMID:25755615
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4284240/
Abstract

Hepatocellular carcinoma (HCC) is different from other malignancies because the prognosis in HCC is not only dependent upon the tumor stage but also on the liver function impairment due to accompanying cirrhosis liver. Various other staging systems used in HCC include the European systems [French staging system, Barcelona Clinic Liver Cancer (BCLC) staging system and the cancer of the liver Italian program (CLIP)] and Asian systems [Okuda staging system, Japan integrated Staging (JIS), Tokyo score and Chinese University Prognostic Index (CUPI)]. Out of all the staging systems used in HCC, Barcelona Clinic Liver Cancer (BCLC) staging system is probably the best because it takes in to account the tumor status (defined by tumor size and number, presence of vascular invasion and extrahepatic spread), liver function (defined either by the Child-Pugh's class) and general health status of the patient (defined by the ECOG classification and the presence of symptoms). Since most of the extrahepatic spread in HCC occurs to lymph nodes, lungs and bones, the assessment can be done with either PET/CT or a combination of CT (Chest and abdomen) and a bone scan. This article describes the various staging systems used in HCC, guides choosing a staging system particularly in the Indian context and the assessment of extra-hepatic spread in HCC.

摘要

肝细胞癌(HCC)与其他恶性肿瘤不同,因为HCC的预后不仅取决于肿瘤分期,还取决于伴发的肝硬化所导致的肝功能损害。HCC中使用的其他各种分期系统包括欧洲系统[法国分期系统、巴塞罗那临床肝癌(BCLC)分期系统和意大利肝癌项目(CLIP)]以及亚洲系统[奥田分期系统、日本综合分期(JIS)、东京评分和中国大学预后指数(CUPI)]。在HCC使用的所有分期系统中,巴塞罗那临床肝癌(BCLC)分期系统可能是最好的,因为它考虑了肿瘤状态(由肿瘤大小和数量、血管侵犯和肝外转移的存在来定义)、肝功能(由Child-Pugh分级定义)以及患者的一般健康状况(由ECOG分类和症状的存在来定义)。由于HCC的大多数肝外转移发生在淋巴结、肺和骨骼,评估可以通过PET/CT或CT(胸部和腹部)与骨扫描的组合来进行。本文描述了HCC中使用的各种分期系统,指导如何选择分期系统,特别是在印度背景下以及如何评估HCC的肝外转移。